Adlai Nortye (NASDAQ:ANL) Director Sells 10,000 Shares of Company Stock

Key Points

• Director Ping Ji sold 10,000 Adlai Nortye shares at an average price of $15.99, generating $159,900. Following the sale, Ji retained 121,453 shares, a 7.61% reduction in the position.
• Adlai Nortye shares fell 1.5% to $15.77 in mid-day trading, while the stock remained near its 52-week high of $17.25.
• Institutional investors own 35.21% of the company, and analysts maintain a consensus “Moderate Buy” rating with an average price target of $29.50, despite mixed individual ratings.

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL - Get Free Report) Director Ping Ji sold 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $15.99, for a total transaction of $159,900.00. Following the completion of the sale, the director owned 121,453 shares in the company, valued at $1,942,033.47. This represents a 7.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Ping Ji also recently made the following trade(s):

• On Tuesday, September 29th, Ping Ji sold 214 shares of Adlai Nortye stock. The shares were sold at an average price of $15.77, for a total value of $3,374.78.
• On Tuesday, September 22nd, Ping Ji sold 5,000 shares of Adlai Nortye stock. The shares were sold at an average price of $16.63, for a total transaction of $83,150.00.

Adlai Nortye Stock Down 1.5%

Shares of NASDAQ ANL traded down $0.23 during mid-day trading on Thursday, reaching $15.77. 9,308 shares of the company were exchanged, compared to its average volume of 364,887. The company's 50 day moving average price is $14.23 and its 200 day moving average price is $12.20. Adlai Nortye Ltd. Sponsored ADR has a 52 week low of $0.88 and a 52 week high of $17.25. The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.65 and a current ratio of 9.55.

Hedge Funds Weigh In On Adlai Nortye

Several hedge funds have recently made changes to their positions in ANL. Seven Fleet Capital Management LP purchased a new stake in shares of Adlai Nortye during the 2nd quarter worth approximately $1,302,000. Braidwell LP purchased a new position in shares of Adlai Nortye in the 2nd quarter worth about $9,145,000. Boone Capital Management LLC purchased a new position in shares of Adlai Nortye in the 2nd quarter valued at $2,971,000. ADAR1 Capital Management LLC acquired a new position in shares of Adlai Nortye during the first quarter worth $816,000. Finally, Affinity Asset Advisors LLC acquired a new stake in Adlai Nortye during the 1st quarter valued at approximately $1,140,000. Hedge funds and other institutional investors own 35.21% of the company's stock.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Wall Street Zen downgraded Adlai Nortye from a "buy" rating to a "hold" rating in a research note on Saturday, September 12th. Jefferies Financial Group began coverage on shares of Adlai Nortye in a research note on Thursday, September 10th. They issued a "buy" rating and a $31.00 target price on the stock. HC Wainwright reissued a "buy" rating and issued a $20.00 price target on shares of Adlai Nortye in a research report on Tuesday, September 8th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Adlai Nortye in a research report on Tuesday, July 14th. Finally, Loop Capital set a $49.00 price objective on shares of Adlai Nortye in a report on Tuesday, September 8th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $29.50.

Adlai Nortye Company Profile

Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company's research and development activities center on oncology and immuno-oncology, with the goal of addressing unmet needs in the treatment of solid tumors.

Adlai Nortye's lead candidate is buparlisib, also known as AN2025, an oral pan-class I phosphoinositide 3-kinase (PI3K) inhibitor being developed for oncology indications, including head and neck cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.